AUG 7, 2026 · PHASE 3 TRIAL
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
ClinicalTrials.gov
This is an active Phase 3 trial registration with no results reported; it describes a planned comparison but cannot yet support clinical evidence or practice guidance.
Reported
Estimated enrollment1000
Primary outcome measure 1Progression Free Survival (PFS), up to appr…
Primary outcome measure 2Overall Survival (OS), up to approximately…